DBPR376-Targeting Small Molecule Mertansine Conjugate for Cancer Treatment(SMDC)
In order to address the impact of side effects on the quality of life of cancer patients during chemotherapy, a new generation of small molecule warhead-drug conjugate technology has been developed. National Health Research Institutes (NHRI) develop the peptide drug conjugate DBPR376 utilizes -Novel Luteinizing Hormone-Releasing Hormone Receptor (LHRH) as the targeting motif to detect signals released by cancer cells and allows accumulation that leads to the increasing cancer drug DM1 concentration in tumors.
National Health Research Institutes (NHRI) is a medical and health research organization in Taiwan, established as a public-funded foundation. Its main research areas include medicine, pharmaceuticals, public health, and other life sciences, as well as related technologies such as vaccine development.
GLUT Targeting Small Molecule Drug Conjugation for Cancer Therapy
Novel Small Molecule AXL and MERTK Dual Tyrosine Kinase Inhibitor as A nti-Tumor and Immunomodulatory Agent
A Site-Specific B7-H3 Targeting Antibody-Drug Conjugate for Cancer Therapy
Innovative Development of Androgen-Metabolizing Probiotics: Functional Gut Microbiome Therapy for Hyperandrogenism Treatment
Technology maturity：Experiment stage
Exhibiting purpose：Technology transactions
Trading preferences：Exclusive license/assignment、New products development、Negotiate by self
*Organization
*Name
*Phone
*Main Purpose
*Discuss Further
*Job Category
*Overall Rating
*Favorite Area
*Key Tech Focus
*Willing to Receive Updates?
Other Suggestions
Coming soon!